{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:03:36Z","timestamp":1793117016118,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40264-023-01392-3","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T12:34:32Z","timestamp":1706186072000},"page":"439-451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5124-0748","authenticated-orcid":false,"given":"Bronya","family":"Calvarysky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0551-4759","authenticated-orcid":false,"given":"Idit","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9145-618X","authenticated-orcid":false,"given":"Daniel","family":"Shepshelovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-345X","authenticated-orcid":false,"given":"Avi","family":"Leader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6211-2073","authenticated-orcid":false,"given":"Talia Diker","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"issue":"4","key":"1392_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","volume":"19","author":"ZZ Htike","year":"2017","unstructured":"Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524\u201336.","journal-title":"Diabetes Obes Metab"},{"issue":"10321","key":"1392_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0140-6736(21)01640-8","volume":"399","author":"Q Shi","year":"2022","unstructured":"Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. The Lancet. 2022;399(10321):259\u201369.","journal-title":"The Lancet"},{"issue":"Suppl 1","key":"1392_CR3","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","volume":"45","author":"B Draznin","year":"2022","unstructured":"American Diabetes Association Professional Practice C, Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, et al. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125\u201343.","journal-title":"Diabetes Care"},{"issue":"1","key":"1392_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12933-021-01281-y","volume":"20","author":"O Mosenzon","year":"2021","unstructured":"Mosenzon O, Del Prato S, Schechter M, Leiter LA, Ceriello A, DeFronzo RA, et al. From glucose lowering agents to disease\/diabetes modifying drugs: a \u201cSIMPLE\u201d approach for the treatment of type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):92.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1392_CR5","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.clinthera.2011.04.024","volume":"33","author":"JJ Neumiller","year":"2011","unstructured":"Neumiller JJ. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin Ther. 2011;33(5):528\u201376.","journal-title":"Clin Ther"},{"issue":"3","key":"1392_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"GL Amidon","year":"1995","unstructured":"Amidon GL, Lennern\u00e4s H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413\u201320.","journal-title":"Pharm Res"},{"issue":"8","key":"1392_CR7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2165\/00003495-200969080-00003","volume":"69","author":"J Ma","year":"2009","unstructured":"Ma J, Rayner CK, Jones KL, Horowitz M. Diabetic gastroparesis: diagnosis and management. Drugs. 2009;69(8):971\u201386.","journal-title":"Drugs"},{"issue":"6","key":"1392_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2165\/00003088-199427060-00004","volume":"27","author":"JM Greiff","year":"1994","unstructured":"Greiff JM, Rowbotham D. Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Clin Pharmacokinet. 1994;27(6):447\u201361.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1392_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003088-199528010-00005","volume":"28","author":"GS Hebbard","year":"1995","unstructured":"Hebbard GS, Sun WM, Bochner F, Horowitz M. Pharmacokinetic considerations in gastrointestinal motor disorders. Clin Pharmacokinet. 1995;28(1):41\u201366.","journal-title":"Clin Pharmacokinet"},{"issue":"372","key":"1392_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372): n71.","journal-title":"BMJ"},{"issue":"6","key":"1392_CR11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.contraception.2016.07.011","volume":"94","author":"EN Berry-Bibee","year":"2016","unstructured":"Berry-Bibee EN, Kim MJ, Simmons KB, Tepper NK, Riley HE, Pagano HP, et al. Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review. Contraception. 2016;94(6):650\u201367.","journal-title":"Contraception"},{"key":"1392_CR12","unstructured":"GUIDELINE IH. FDA M9-Biopharmaceutics-Classification-System-Based-Biowaivers.pdf. 2018. https:\/\/www.fda.gov\/media\/148472\/download. Accessed 20 Aug 2023."},{"issue":"5","key":"1392_CR13","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1177\/0091270004274432","volume":"45","author":"E Blase","year":"2005","unstructured":"Blase E, Taylor K, Gao HY, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol. 2005;45(5):570\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1392_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3810\/pgm.2012.11.2613","volume":"124","author":"M Bush","year":"2012","unstructured":"Bush M, Scott R, Watanalumlerd P, Zhi H, Lewis E. Effects of multiple doses of Albiglutide on the pharmacokinetics, Pharmacodynamics, and safety of Digoxin, Warfarin, or a low-dose oral contraceptive. Postgrad Med. 2012;124(6):55\u201372.","journal-title":"Postgrad Med"},{"issue":"11","key":"1392_CR15","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s40262-017-0531-7","volume":"56","author":"A de la Pe\u00f1a","year":"2017","unstructured":"de la Pe\u00f1a A, Cui X, Geiser J, Loghin C. No dose adjustment is recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. Clin Pharmacokinet. 2017;56(11):1415\u201327.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1392_CR16","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40262-017-0532-6","volume":"56","author":"H Hausner","year":"2017","unstructured":"Hausner H, DervingKarsb\u00f8l J, Holst AG, Jacobsen JB, Wagner FD, Golor G, et al. Effect of semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. Clin Pharmacokinet. 2017;56(11):1391\u2013401.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1392_CR17","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1177\/0091270010389471","volume":"51","author":"LV Jacobsen","year":"2011","unstructured":"Jacobsen LV, Vouis J, Hindsberger C, Zdravkovic M. Treatment with liraglutide-a once-daily GLP-1 analog-does not reduce the bioavailability of ethinyl estradiol\/levonorgestrel taken as an oral combination contraceptive drug. J Clin Pharmacol. 2011;51(12):1696\u2013703.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1392_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/jcph.443","volume":"55","author":"C Kapitza","year":"2015","unstructured":"Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol\/levonorgestrel. J Clin Pharmacol. 2015;55(5):497\u2013504.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"1392_CR19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s12325-011-0044-y","volume":"28","author":"C Kapitza","year":"2011","unstructured":"Kapitza C, Zdravkovic M, Hindsberger C, Flint A. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. Adv Ther. 2011;28(8):650\u201360.","journal-title":"Adv Ther"},{"issue":"2","key":"1392_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.5414\/CPP45114","volume":"45","author":"PA Kothare","year":"2007","unstructured":"Kothare PA, Linnebjerg H, Skrivanek Z, Reddy S, Mace K, Pena A, et al. Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther. 2007;45(2):114\u201320.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1392_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-12-8","author":"PA Kothare","year":"2012","unstructured":"Kothare PA, Seger ME, Northrup J, Mace K, Mitchell MI, Linnebjerg H. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. BMC Clin Pharmacol. 2012. https:\/\/doi.org\/10.1186\/1472-6904-12-8.","journal-title":"BMC Clin Pharmacol"},{"issue":"9","key":"1392_CR22","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1177\/0091270005278806","volume":"45","author":"PA Kothare","year":"2005","unstructured":"Kothare PA, Soon DKW, Linnebjerg H, Park S, Chan C, Yeo A, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 2005;45(9):1032\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"1392_CR23","doi-asserted-by":"publisher","first-page":"651","DOI":"10.5414\/CPP47651","volume":"47","author":"H Linnebjerg","year":"2009","unstructured":"Linnebjerg H, Kothare P, Park S, Mace K, Mitchell M. The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension. Int J Clin Pharmacol Ther. 2009;47(11):651\u20138.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"1392_CR24","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1021\/acs.molpharmaceut.5b00278","volume":"12","author":"M Malm-Erjef\u00e4lt","year":"2015","unstructured":"Malm-Erjef\u00e4lt M, Ekblom M, Vouis J, Zdravkovic M, Lennern\u00e4s H. Effect on the gastrointestinal absorption of drugs from different classes in the biopharmaceutics classification system, when treating with liraglutide. Mol Pharm. 2015;12(11):4166\u201373.","journal-title":"Mol Pharm"},{"issue":"10","key":"1392_CR25","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/0091270006291622","volume":"46","author":"D Soon","year":"2006","unstructured":"Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol. 2006;46(10):1179\u201387.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"1392_CR26","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.2337\/dc13-1066","volume":"36","author":"NR Pinelli","year":"2013","unstructured":"Pinelli NR, Patel A, Salinitri FD. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. Diabetes Care. 2013;36(10):e171\u20132.","journal-title":"Diabetes Care"},{"issue":"4","key":"1392_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.962","volume":"10","author":"EK Langeskov","year":"2022","unstructured":"Langeskov EK, Kristensen K. Population pharmacokinetic of paracetamol and atorvastatin with co-administration of semaglutide. Pharmacol Res Perspect. 2022;10(4): e00962.","journal-title":"Pharmacol Res Perspect"},{"issue":"7","key":"1392_CR28","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.2337\/diabetes.54.7.2212","volume":"54","author":"JJ Meier","year":"2005","unstructured":"Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes. 2005;54(7):2212\u20138.","journal-title":"Diabetes"},{"issue":"7","key":"1392_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3810\/pgm.2014.11.2836","volume":"126","author":"MA Young","year":"2014","unstructured":"Young MA, Wald JA, Matthews JE, Scott R, Hodge RJ, Zhi H, et al. Clinical pharmacology of albiglutide, a glp-1 receptor agonist. Postgrad Med. 2014;126(7):84\u201397.","journal-title":"Postgrad Med"},{"key":"1392_CR30","first-page":"89","volume":"109","author":"R Dahmen","year":"2011","unstructured":"Dahmen R, Steinstraesser A, Poitiers F, Ozoux ML, Pinquier JL. Interaction of subcutaneous lixisenatide 20 lg QD on pharmacokinetic and pharmacodynamic properties of oral ramipril 5 MG QD in. Basic Clin Pharmacol Toxicol. 2011;109:89.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1392_CR31","unstructured":"Liu YH, Ruus P, Steinstraesser A, Teichert L. Effect of the GLP-1 agonist lixisenatide on the pharmacokinetics of warfarin. In: Abstract conference: 70th scientific sessions of the American Diabetes Association. 2010."},{"key":"1392_CR32","first-page":"S53","volume":"45","author":"LS Tham","year":"2018","unstructured":"Tham LS, Schneck KB, Geiser JS, Posada M, Dickinson G. Integration of population exposure-response and physiological based pharmacokinetics modeling approaches to evaluate gastric-emptying induced drug interaction risks for dulaglutide. J Pharmacokinet Pharmacodyn. 2018;45:S53\u20134.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"1392_CR33","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1499","volume":"36","author":"Y Fujita","year":"2013","unstructured":"Fujita Y, Kitamura T, Otsuki M, Tamada D, Tabuchi Y, Kozawa J, et al. Exenatide alters absorption of hydrocortisone in a diabetic patient with panhypopituitarism: Iatrogenic adrenal insufficiency. Diabetes Care. 2013;36(1): e8.","journal-title":"Diabetes Care"},{"issue":"7","key":"1392_CR34","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2169\/internalmedicine.1585-18","volume":"58","author":"Y Nagai","year":"2019","unstructured":"Nagai Y, Mukai K, Otsuki M, Kimura T, Kozawa J, Nishizawa H, et al. Suppression failure of cortisol secretion by dexamethasone may occur in glucagon-like peptide-1 receptor agonist-treated patients with diabetic autonomic neuropathy. Intern Med. 2019;58(7):949\u201353.","journal-title":"Intern Med"},{"key":"1392_CR35","unstructured":"FDA. Exenatide prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021773s9s11s18s22s25lbl.pdf"},{"key":"1392_CR36","unstructured":"FDA. Lixisenatide prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208471orig1s000lbl.pdf"},{"key":"1392_CR37","unstructured":"FDA. Liraglutide prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022341lbl.pdf"},{"key":"1392_CR38","unstructured":"FDA. Dulaglutide prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125469s007s008lbl.pdf"},{"key":"1392_CR39","unstructured":"FDA. Albiglutide prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125431s019lbl.pdf"},{"key":"1392_CR40","unstructured":"FDA. Semaglutide prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf"},{"issue":"347","key":"1392_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5298","volume":"12","author":"BH Stegeman","year":"2013","unstructured":"Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama VA, Helmerhorst FM, Stijnen T, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ. 2013;12(347): f5298.","journal-title":"BMJ"},{"key":"1392_CR42","unstructured":"Industry FGf. Clinical drug interaction studies with combined oral contraceptives. 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-combined-oral-contraceptives-guidance-industry. Accessed 20 Aug 2023."},{"issue":"10","key":"1392_CR43","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1023\/A:1011935603893","volume":"46","author":"M Willems","year":"2001","unstructured":"Willems M, Quartero AO, Numans ME. How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Dig Dis Sci. 2001;46(10):2256\u201362.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"1392_CR44","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0009-9236(96)90218-0","volume":"60","author":"DD Cilla Jr","year":"1996","unstructured":"Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther. 1996;60(6):687\u201395.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1392_CR45","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2165\/11535980-000000000-00000","volume":"49","author":"R Narwal","year":"2010","unstructured":"Narwal R, Akhlaghi F, Asberg A, Hermann M, Rosenbaum SE. Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. Clin Pharmacokinet. 2010;49(10):693\u2013702.","journal-title":"Clin Pharmacokinet"},{"key":"1392_CR46","unstructured":"EMA. Investigation of drug interactions. https:\/\/www.ema.europa.eu\/en\/investigation-drug-interactions"},{"key":"1392_CR47","unstructured":"FDA. Drug Interactions | Relevant regulatory guidance and policy documents. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-interactions-relevant-regulatory-guidance-and-policy-documents"},{"issue":"12","key":"1392_CR48","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00125-022-05796-1","volume":"65","author":"RJ Jalleh","year":"2022","unstructured":"Jalleh RJ, Jones KL, Rayner CK, Marathe CS, Wu T, Horowitz M. Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control. Diabetologia. 2022;65(12):1981\u201393.","journal-title":"Diabetologia"},{"issue":"12","key":"1392_CR49","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1111\/dom.14166","volume":"22","author":"M Horowitz","year":"2020","unstructured":"Horowitz M, Rayner CK, Marathe CS, Wu T, Jones KL. Glucagon-like peptide-1 receptor agonists and the appropriate measurement of gastric emptying. Diabetes Obes Metab. 2020;22(12):2504\u20136.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1392_CR50","first-page":"E981","volume":"273","author":"MA Nauck","year":"1997","unstructured":"Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5):E981\u20138.","journal-title":"Am J Physiol"},{"issue":"3","key":"1392_CR51","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/dom.12593","volume":"18","author":"MM Smits","year":"2016","unstructured":"Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Cahen DL, van Raalte DH. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab. 2016;18(3):224\u201335.","journal-title":"Diabetes Obes Metab"},{"issue":"9645","key":"1392_CR52","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","volume":"372","author":"DJ Drucker","year":"2008","unstructured":"Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. The Lancet. 2008;372(9645):1240\u201350.","journal-title":"The Lancet"},{"issue":"5","key":"1392_CR53","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2337\/db10-0474","volume":"60","author":"MA Nauck","year":"2011","unstructured":"Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561\u20135.","journal-title":"Diabetes"},{"issue":"3","key":"1392_CR54","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1046\/j.1464-5491.2002.00658.x","volume":"19","author":"M Horowitz","year":"2002","unstructured":"Horowitz M, O\u2019Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med. 2002;19(3):177\u201394.","journal-title":"Diabet Med"},{"issue":"11","key":"1392_CR55","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1038\/oby.2004.213","volume":"12","author":"J Xing","year":"2004","unstructured":"Xing J, Chen JD. Alterations of gastrointestinal motility in obesity. Obes Res. 2004;12(11):1723\u201332.","journal-title":"Obes Res"},{"issue":"4","key":"1392_CR56","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/a-0818-6374","volume":"51","author":"C Beti","year":"2019","unstructured":"Beti C, Stratmann B, Bokman G, Dreier J, Hauber M, Lee-Barkey YH, et al. Exenatide delays gastric emptying in patients with type 2 diabetes mellitus but not in those with gastroparetic conditions. Horm Metab Res. 2019;51(4):267\u201373.","journal-title":"Horm Metab Res"},{"issue":"11","key":"1392_CR57","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s11695-008-9415-0","volume":"17","author":"O Bourron","year":"2007","unstructured":"Bourron O, Ciangura C, Bouillot JL, Massias L, Poitou C, Oppert JM. Amiodarone-induced hyperthyroidism during massive weight loss following gastric bypass. Obes Surg. 2007;17(11):1525\u20138.","journal-title":"Obes Surg"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01392-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01392-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01392-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T10:38:39Z","timestamp":1723027119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01392-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1392"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01392-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"assertion":[{"value":"17 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Tel Aviv University. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"BC declares that there are no relationships or activities that might bias, or be perceived to bias, her work. ID has received fees from Astra Zeneca, Novo Nordisk, Abbott, Boehringer Ingleheim, Elli Lilly and Sanofi for educational lectures, and participated in advisory boards of Novo Nordisk, Boehringer Ingleheim, Sanofi and Novartis that are outside the scope of this work. ID reports a grant from Astra Zeneca that is outside the scope of the submitted work. DS declares that there are no relationships or activities that might bias, or be perceived to bias, his work. AL declares that there are no relationships or activities that might bias, or be perceived to bias, his work. TDC has received fees from Astra Zeneca for educational lectures that are outside the scope of this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data are available on request from the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication\/Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Design \u2013 BC and TDC. Conduct\/data collection \u2013 BC and TDC. Analysis \u2013 BC, ID, DS, AL and TDC. Writing manuscript \u2013 BC, ID, DS, AL and TDC.\u00a0All authors read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}